SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)

被引：0
|
作者：
Hecht, J. R. [1 ]
Cohn, A. [2 ]
Dakhil, S. [3 ]
Saleh, M.
Cline-Burkhardt, M. [4 ]
Piperdi, B. [5 ]
Tian, Y. [6 ]
Go, W. [6 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Kansas, Liberal, KS USA
[4] US Oncol, Austin, TX USA
[5] Montefiore Med Ctr, New York, NY USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [21] Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
  • [22] A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
    Shitara, Kohei
    Yonesaka, Kimio
    Denda, Tadamichi
    Yamazaki, Kentaro
    Moriwaki, Toshikazu
    Tsuda, Masahiro
    Takano, Toshimi
    Okuda, Hiroyuki
    Nishina, Tomohiro
    Sakai, Kazuko
    Nishio, Kazuto
    Tokunaga, Shoji
    Yamanaka, Takeharu
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study
    Bennouna, J.
    Husseini, F.
    Delord, J. P.
    Borg, C.
    Trillet-Lenoir, V.
    Faroux, R.
    Francois, E.
    Ychou, M.
    Chaaban, B.
    Douillard, J. Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 344
  • [24] Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
    Peeters, M.
    Price, T. J.
    Strickland, A. H.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M. M.
    Spigel, D. R.
    Tian, Y.
    Krishnan, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [26] Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice
    Sugimoto, N.
    Hasegawa, A.
    Fujisawa, F.
    Yoshinami, T.
    Yagi, T.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    De Stefano, Alfonso
    Rosati, Gerardo
    Lolli, Ivan
    Tamburini, Emiliano
    Colombo, Alfredo
    Santini, Daniele
    Silvestro, Lucrezia
    Facchini, Gaetano
    Mannavola, Francesco
    Febbraro, Antonio
    Troncone, Giancarlo
    Sobrero, Alberto F.
    Giannarelli, Diana
    Budillon, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only.
    Zakari, Ahmed
    Gian, Victor G.
    Meluch, Anthony Alan
    Peyton, James D.
    Waterhouse, David Michael
    Lipman, Andrew J.
    Boccia, Ralph V.
    Jones, Suzanne Fields
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
    Peeters, Marc
    Oliner, Kelly Smith
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor E.
    Roman, Laslo
    Van Cutsem, Eric
    Yu, Hua
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
12345